Our previous work in AML showing that INPP4B is highly expressed and associated with adverse outcome in 25% of AML patients [17] exemplified the value of a non-median dichotomization approach and recognized the existence of small, prognostically distinct subgroups within a population. The gene discussed is INPP4B; the disease is acute myeloid leukemia.